168 related articles for article (PubMed ID: 35759904)
1. The disease course of multiple sclerosis before and during COVID-19 pandemic: A retrospective five-year study.
Babtain F; Bajafar A; Nazmi O; Badawi M; Basndwah A; Bushnag A; Cupler E; Hassan A
Mult Scler Relat Disord; 2022 Sep; 65():103985. PubMed ID: 35759904
[TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2 pandemic as a model to assess the relationship between intercurrent viral infections and disease activity in Multiple Sclerosis: A propensity score matched case-control study.
Vercellino M; Bosa C; Alteno A; Muccio F; Marasciulo S; Garelli P; Cavalla P
Mult Scler Relat Disord; 2023 Jun; 74():104715. PubMed ID: 37058763
[TBL] [Abstract][Full Text] [Related]
3. Effect of the COVID-19 pandemic on disease activity in multiple sclerosis patients treated with hematopoietic stem cell transplantation.
Mariottini A; Lotti A; Innocenti C; Repice AM; Nozzoli C; Boncompagni R; Fainardi E; Saccardi R; Massacesi L
Eur J Neurol; 2023 Oct; 30(10):3362-3366. PubMed ID: 37483174
[TBL] [Abstract][Full Text] [Related]
4. Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort.
Tilling K; Lawton M; Robertson N; Tremlett H; Zhu F; Harding K; Oger J; Ben-Shlomo Y
Health Technol Assess; 2016 Oct; 20(81):1-48. PubMed ID: 27817792
[TBL] [Abstract][Full Text] [Related]
5. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
6. Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes.
Yano H; Gonzalez C; Healy BC; Glanz BI; Weiner HL; Chitnis T
Mult Scler Relat Disord; 2019 Oct; 35():119-127. PubMed ID: 31374460
[TBL] [Abstract][Full Text] [Related]
7. A one year follow of patients with multiple sclerosis during COVID-19 pandemic: A cross-sectional study in Qom province, Iran.
Paybast S; Hejazi SA; Molavi P; Habibi MA; Naser Moghadasi A
Mult Scler Relat Disord; 2022 Apr; 60():103712. PubMed ID: 35247752
[TBL] [Abstract][Full Text] [Related]
8. Discontinuation of disease-modifying treatments in multiple sclerosis to plan a pregnancy: A retrospective registry study.
Villaverde-González R; Candeliere-Merlicco A; Alonso-Frías MA; Aparicio Castro E; Carrillo Alcaraz A; Mallada Frechín J; Pérez Sempere Á
Mult Scler Relat Disord; 2020 Nov; 46():102518. PubMed ID: 32977075
[TBL] [Abstract][Full Text] [Related]
9. Discontinuation of disease-modifying therapy in MS patients over 60 years old and its impact on relapse rate and disease progression.
Salavisa M; Serrazina F; Ladeira AF; Correia AS
Clin Neurol Neurosurg; 2023 Feb; 225():107612. PubMed ID: 36701940
[TBL] [Abstract][Full Text] [Related]
10. Clinical course and outcome of SARS-CoV-2 infection in multiple sclerosis patients treated with disease-modifying therapies - the Polish experience.
Czarnowska A; Brola W; Zajkowska O; Rusek S; Adamczyk-Sowa M; Kubicka-Bączyk K; Kalinowska-Łyszczarz A; Kania K; Słowik A; Wnuk M; Marona M; Podlecka-Piętowska A; Nojszewska M; Zakrzewska-Pniewska B; Jasińska E; Gołuch K; Lech B; Noga M; Perenc A; Popiel M; Lasek-Bal A; Puz P; Maciejowska K; Kucharska-Lipowska M; Lipowski M; Kapica-Topczewska K; Chorąży M; Tarasiuk J; Kochanowicz J; Kulikowska J; Wawrzyniak S; Niezgodzińska-Maciejek A; Pokryszko-Dragan A; Gruszka E; Budrewicz S; Białek M; Kurkowska-Jastrzębska I; Kurowska K; Stępień A; Włodek A; Ptasznik V; Pawełczyk M; Sobolewski P; Lejmel H; Strzalińska K; Maciejowski M; Tutaj A; Zwiernik J; Litwin A; Lewańczyk B; Paprocka I; Zwiernik B; Pawlos A; Borysowicz A; Narożnik A; Michałowska A; Nosek K; Fudala M; Milewska-Jędrzejczak M; Kułakowska A; Bartosik-Psujek H
Neurol Neurochir Pol; 2021; 55(2):212-222. PubMed ID: 33856686
[TBL] [Abstract][Full Text] [Related]
11. Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study.
Iaffaldano P; Lucisano G; Manni A; Paolicelli D; Patti F; Capobianco M; Brescia Morra V; Sola P; Pesci I; Lus G; De Luca G; Lugaresi A; Cavalla P; Montepietra S; Maniscalco GT; Granella F; Ragonese P; Vianello M; Brambilla L; Totaro R; Toscano S; Malucchi S; Petracca M; Moiola L; Ferraro D; Lepore V; Mosconi P; Ponzio M; Tedeschi G; Comi G; Battaglia MA; Filippi M; Amato MP; Trojano M;
Neurol Neuroimmunol Neuroinflamm; 2022 Mar; 9(2):. PubMed ID: 35046084
[TBL] [Abstract][Full Text] [Related]
12. Management of worsening multiple sclerosis with mitoxantrone: a review.
Fox EJ
Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
[TBL] [Abstract][Full Text] [Related]
13. Influence of delaying ocrelizumab dosing in multiple sclerosis due to COVID-19 pandemics on clinical and laboratory effectiveness.
Barun B; Gabelić T; Adamec I; Babić A; Lalić H; Batinić D; Krbot Skorić M; Habek M
Mult Scler Relat Disord; 2021 Feb; 48():102704. PubMed ID: 33370649
[TBL] [Abstract][Full Text] [Related]
14. Is breastfeeding in MS harmful or not? An answer from real-world Czech data.
Hradilek P; Zapletalova O; Hanulikova P; Havrdova EK; Woznicova I; Mazouchova A; Drahota J; Lauer M; Stetkarova I; Valis M; Libertinova J; Stourac P; Adamkova J; Ampapa R; Vachova M; Dufek M; Martinková A; Peterka M; Recmanova E; Mares J; Horakova D
Mult Scler Relat Disord; 2023 Aug; 76():104790. PubMed ID: 37348317
[TBL] [Abstract][Full Text] [Related]
15. Comparative Efficacy of Relapsing Multiple Sclerosis Therapies: Model-Based Meta-Analyses for Confirmed Disability Accumulation and Annualized Relapse Rate.
Hennessy B; Zierhut ML; Kracker H; Keenan A; Sidorenko T
Mult Scler Relat Disord; 2022 Aug; 64():103908. PubMed ID: 35803162
[TBL] [Abstract][Full Text] [Related]
16. COVID-19 and its implications on the clinico-radiological course of multiple sclerosis: A case-control study.
Rahmani M; Moghadasi AN; Shahi S; Eskandarieh S; Azizi H; Hasanzadeh A; Ahmadzade A; Dehnavi AZ; Farahani RH; Aminianfar M; Naeini AR
Med Clin (Barc); 2023 Mar; 160(5):187-192. PubMed ID: 36089420
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic inertia in relapsing-remitting multiple sclerosis.
Rodrigues R; Rocha R; Bonifácio G; Ferro D; Sabença F; Gonçalves AI; Correia F; Pinheiro J; Loureiro JL; Guerreiro RP; Vale J; Sá MJ; Costa A
Mult Scler Relat Disord; 2021 Oct; 55():103176. PubMed ID: 34343868
[TBL] [Abstract][Full Text] [Related]
18. Clinical predictors of Dimethyl Fumarate response in multiple sclerosis: a real life multicentre study.
Lanzillo R; Moccia M; Palladino R; Signoriello E; Carotenuto A; Maniscalco GT; Saccà F; Bonavita S; Russo CV; Iodice R; Petruzzo M; Sinisi L; De Angelis M; Lavorgna L; De Rosa A; Romano F; Orlando V; Ronga B; Florio C; Lus G; Brescia Morra V
Mult Scler Relat Disord; 2020 Feb; 38():101871. PubMed ID: 31786463
[TBL] [Abstract][Full Text] [Related]
19. Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic.
Zanghì A; Avolio C; Signoriello E; Abbadessa G; Cellerino M; Ferraro D; Messina C; Barone S; Callari G; Tsantes E; Sola P; Valentino P; Granella F; Patti F; Lus G; Bonavita S; Inglese M; D'Amico E
Neurotherapeutics; 2022 Sep; 19(5):1535-1545. PubMed ID: 36036858
[TBL] [Abstract][Full Text] [Related]
20. Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial.
Burt RK; Balabanov R; Burman J; Sharrack B; Snowden JA; Oliveira MC; Fagius J; Rose J; Nelson F; Barreira AA; Carlson K; Han X; Moraes D; Morgan A; Quigley K; Yaung K; Buckley R; Alldredge C; Clendenan A; Calvario MA; Henry J; Jovanovic B; Helenowski IB
JAMA; 2019 Jan; 321(2):165-174. PubMed ID: 30644983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
